Cytokinetics Incorporated (NASDAQ:CYTK) went up by 2.62% from its latest closing price compared to the recent 1-year high of $30.14. The company’s stock price has collected 9.16% of gains in the last five trading sessions. Press Release reported on 12/01/20 that Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Get the hottest stocks to trade every day before the market opens 100% free. Click here now.
Is It Worth Investing in Cytokinetics Incorporated (NASDAQ :CYTK) Right Now?
Plus, the 36-month beta value for CYTK is at 1.42. Opinions of the stock are interesting as 7 analysts out of 9 who provided ratings for Cytokinetics Incorporated declared the stock was a “buy,” while 1 rated the stock as “overweight,” 1 rated it as “hold,” and 0 as “sell.”
The average price from analysts is $24.44, which is $6.44 above the current price. CYTK currently public float of 63.85M and currently shorts hold a 13.78% ratio of that float. Today, the average trading volume of CYTK was 1.63M shares.
CYTK’s Market Performance
CYTK stocks went up by 9.16% for the week, with a monthly jump of 12.85% and a quarterly performance of -27.21%, while its annual performance rate touched 84.05%. The volatility ratio for the week stands at 4.59% while the volatility levels for the past 30 days are set at 6.07% for Cytokinetics Incorporated. The simple moving average for the period of the last 20 days is 8.15% for CYTK stocks with a simple moving average of -5.47% for the last 200 days.
Analysts’ Opinion of CYTK
Many brokerage firms have already submitted their reports for CYTK stocks, with Goldman repeating the rating for CYTK by listing it as a “Neutral.” The predicted price for CYTK in the upcoming period, according to Goldman is $16 based on the research report published on October 29th of the current year 2020.
Raymond James, on the other hand, stated in their research note that they expect to see CYTK reach a price target of $39. The rating they have provided for CYTK stocks is “Strong Buy” according to the report published on July 10th, 2020.
Mizuho gave a rating of “Buy” to CYTK, setting the target price at $31 in the report published on May 05th of the current year.
CYTK Trading at -0.64% from the 50-Day Moving Average
After a stumble in the market that brought CYTK to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -40.28% of loss for the given period.
Volatility was left at 6.07%, however, over the last 30 days, the volatility rate increased by 4.59%, as shares surge +7.66% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -12.54% lower at present.
During the last 5 trading sessions, CYTK rose by +9.16%, which changed the moving average for the period of 200-days by +14.47% in comparison to the 20-day moving average, which settled at $16.71. In addition, Cytokinetics Incorporated saw 69.65% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at CYTK starting from Blum Robert I, who sale 5,000 shares at the price of $15.73 back on Nov 23. After this action, Blum Robert I now owns 304,868 shares of Cytokinetics Incorporated, valued at $78,644 using the latest closing price.
Malik Fady Ibraham, the EVP Research & Development of Cytokinetics Incorporated, sale 1,231 shares at $17.15 during a trade that took place back on Nov 12, which means that Malik Fady Ibraham is holding 150,951 shares at $21,112 based on the most recent closing price.
Stock Fundamentals for CYTK
Current profitability levels for the company are sitting at:
- -367.97 for the present operating margin
The net margin for Cytokinetics Incorporated stands at -452.93. The total capital return value is set at -102.20, while invested capital returns managed to touch -130.67.
Get the hottest stocks to trade every day before the market opens 100% free. Click here now.
When we switch over and look at the enterrpise to sales, we see a ratio of 19.42, with the company’s debt to enterprise value settled at 0.26. The receivables turnover for the company is 4.50 and the total asset turnover is 0.11. The liquidity ratio also appears to be rather interesting for investors as it stands at 8.98.
